Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English | Polski
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""MONTALBAN, X"" wg kryterium: Wszystkie pola

  Lista filtrów

Ogranicz do:

Wyrównaj
Wyświetlanie 1-20 z 8174
Podgląd okładki
Tytuł :
Role of B Cells in Multiple Sclerosis and Related Disorders.
Autorzy :
Comi G; Institute of Experimental Neurology, San Raffaele Hospital, Milan, Italy.
Bar-Or A; Department of Neurology, Center for Neuroinflammation and Neurotherapeutics, University of Pennsylvania, Philadelphia, PA.
Lassmann H; Department of Neuroimmunology (Center for Brain Research), University Hospital Vienna, Vienna, Austria.
Uccelli A; Department of Neuroscience, Genetic Ophthalmology, and Infant Maternity Science, San Martino Polyclinic Hospital, Genoa, Italy.
Hartung HP; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Montalban X; Neurology-Neuroimmunology Department and Neurorehabilitation Unit, Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Sørensen PS; Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Hohlfeld R; Institute of Clinical Neuroimmunology, Ludwig Maximilians University of Munich and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Hauser SL; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Pokaż więcej
Corporate Authors :
Expert Panel of the 27th Annual Meeting of the European Charcot Foundation
Źródło :
Annals of neurology [Ann Neurol] 2021 Jan; Vol. 89 (1), pp. 13-23. Date of Electronic Publication: 2020 Nov 04.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
Autorzy :
Zabalza A; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Cárdenas-Robledo S; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tagliani P; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arrambide G; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Otero-Romero S; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Carbonell-Mirabent P; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rodriguez-Barranco M; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rodríguez-Acevedo B; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Restrepo Vera JL; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Resina-Salles M; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Midaglia L; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vidal-Jordana A; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Río J; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Galan I; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Castillo J; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Cobo-Calvo Á; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Comabella M; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Nos C; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sastre-Garriga J; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tintore M; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
European journal of neurology [Eur J Neurol] 2020 Dec 19. Date of Electronic Publication: 2020 Dec 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease‐related disability.
Autorzy :
Vidal‐Jordana, A.
Pareto, D.
Cabello, S.
Alberich, M.
Rio, J.
Tintore, M.
Auger, C.
Montalban, X.
Rovira, A.
Sastre‐Garriga, J.
Pokaż więcej
Temat :
OPTICAL coherence tomography
SPINAL cord
MULTIPLE sclerosis
LOGISTIC regression analysis
ATROPHY
OPTICIANS
Źródło :
European Journal of Neurology; Nov2020, Vol. 27 Issue 11, p2225-2232, 8p
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS.
Autorzy :
Fissolo N; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Matute-Blanch C; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Osman M; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Costa C; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Pinteac R; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Miró B; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Sanchez A; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Brito V; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Dujmovic I; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Voortman M; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Khalil M; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Borràs E; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Sabidó E; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Issazadeh-Navikas S; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Montalban X; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada.
Comabella Lopez M; From the Servei de Neurologia-Neuroimmunologia (N.F., C.M.-B., C.C., R.P., V.B., X.M., M.C.L.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Biotech Research and Innovation Centre (BRIC) (M.O., S.I.-N.), University of Copenhagen, Denmark; Statistics and Bioinformatics Unit (B.M., A.S.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Genetics, Microbiology and Statistics Department (A.S.), Universitat de Barcelona, Spain; Department of Neurology (I.D.), University of Belgrade School of Medicine, Serbia; Department of Neurology (I.D.), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (M.V., M.K.), Medical University of Graz, Austria; Proteomics Unit (E.B., E.S.), Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Spain; Proteomics Unit (E.B., E.S.), Universitat Pompeu Fabra, Barcelona, Spain; and Center for Multiple Sclerosis (X.M.), St. Michael's Hospital, University of Toronto, ON, Canada. .
Pokaż więcej
Źródło :
Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2021 Jan 12; Vol. 8 (2). Date of Electronic Publication: 2021 Jan 12 (Print Publication: 2021).
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
Autorzy :
Kalkers NF; Department of Neurology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands/Department of Neurology, OLVG, Amsterdam, The Netherlands.
Galan I; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Kerbrat A; Department of Neurology, Rennes University Hospital, Rennes, France.
Tacchino A; Scientific Research Area, Italian MS Foundation (FISM), Genoa, Italy.
Kamm CP; Neurology and Neurorehabilitation Center, Lucerne Cantonal Hospital, Lucerne, Switzerland/Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
O'Connell K; Department of Neurology, St. Vincent's University Hospital and University College Dublin, Dublin, Ireland.
McGuigan C; Department of Neurology, St Vincent's University Hospital and University College Dublin, Dublin, Ireland.
Edan G; Department of Neurology, Rennes University Hospital, Rennes, France.
Montalban X; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain/Department of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Uitdehaag BM; Department of Neurology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
Mokkink LB; Department of Epidemiology and Biostatistics, Amsterdam UMC, Location VUmc and Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2021 Jan; Vol. 27 (1), pp. 90-96. Date of Electronic Publication: 2019 Dec 17.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
Autorzy :
Toboso I; Immunology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Tejeda-Velarde A; Immunology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Alvarez-Lafuente R; Instituto de Investigación Sanitaria San Carlos (IDISSC), Hospital Clinico San Carlos, Madrid, Spain.
Arroyo R; Department of Neurology, Hospital Universitario Quiron Salud, Madrid, Spain.
Hegen H; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Deisenhammer F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Sainz de la Maza S; Neurology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Alvarez-Cermeño JC; Neurology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Izquierdo G; Neurology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Paramo D; Neurology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Oliva P; Neurology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Casanova B; Neurology Department, Hospital Universitario la Fe, Valencia, Spain.
Agüera-Morales E; Neurology Department, Hospital Universitario Reina Sofia, Cordoba, Spain.
Franciotta D; Istituti di Recovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy.
Gastaldi M; Istituti di Recovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy.
Fernández O; Neurology Department, Hospital Regional Universitario, Malaga, Spain.
Urbaneja P; Neurology Department, Hospital Regional Universitario, Malaga, Spain.
Garcia-Dominguez JM; Neurology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Romero F; Neurology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Laroni A; University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
Uccelli A; University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
Perez-Sempere A; Neurology Department, Hospital General Universitario de Alicante, Alicante, Spain.
Saiz A; Neurology Service, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Blanco Y; Neurology Service, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Galimberti D; Centro Dino Ferrari, Fondazione Ca' Granda, Istituti di Recovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico, University of Milan, Milan, Italy.
Scarpini E; Centro Dino Ferrari, Fondazione Ca' Granda, Istituti di Recovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico, University of Milan, Milan, Italy.
Espejo C; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rasche L; Department of Neurology, NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Paul F; Department of Neurology, NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
González I; Neurology Department, Hospital Alvaro Cunqueiro, Vigo, Spain.
Álvarez E; Neurology Department, Hospital Alvaro Cunqueiro, Vigo, Spain.
Ramo C; Neurology Department, Hospital Germans Trias i Pujol, Badalona, Spain.
Caminero AB; Neurology Department, Hospital Nuestra Señora de Sonsoles, Avila, Spain.
Aladro Y; Neurology Department, Hospital Universitario Getafe, Getafe, Spain.
Calles C; Neurology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
Eguía P; Neurology Department, Hospital Doctor Jose Molina Orosa, Arrecife, Spain.
Belenguer-Benavides A; Neurology Department, Hospital General Universitario de Castellón, Castellón, Spain.
Ramió-Torrentà L; Neurology Department, Hospital Universitario Doctor Josep Trueta, Girona, Spain.
Quintana E; Neurology Department, Hospital Universitario Doctor Josep Trueta, Girona, Spain.
Martínez-Rodríguez JE; Neurology Department, Hospital del Mar, Barcelona, Spain.
Oterino A; Neurology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
López de Silanes C; Neurology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain.
Casanova LI; Neurology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain.
Landete L; Neurology Department, Hospital Universitario Dr. Peset, Valencia, Spain.
Frederiksen J; Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark.
Bsteh G; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Mulero P; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Comabella M; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Hernández MA; Neurology Department, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain.
Espiño M; Immunology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Prieto JM; Neurology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain.
Pérez D; Neurology Department, Hospital del Bierzo, Ponferrada, Spain.
Otano M; Neurology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Padilla F; Neurology Department, Hospital Clinico de Malaga, Malaga, Spain.
García-Merino JA; Neurology Department, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain.
Navarro L; Neurology Department, Hospital General de Elche, Elche, Spain.
Muriel A; Biostatistics Unit, Hospital Univesitario Ramon y Cajal, Instituto Ramon y Cajal para la Investigación Sanitaria (IRYCIS), Madrid, Spain.
Frossard LC; Neurology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Villar LM; Immunology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Pokaż więcej
Źródło :
Frontiers in neurology [Front Neurol] 2020 Dec 17; Vol. 11, pp. 579438. Date of Electronic Publication: 2020 Dec 17 (Print Publication: 2020).
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
Autorzy :
Comabella M; Montalban Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Deutschmann C; Faculty Environment and Natural Sciences, Institute of Biotechnology, Senftenberg, Germany.
Midaglia L; Montalban Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Schierack P; Faculty Environment and Natural Sciences, Institute of Biotechnology, Senftenberg, Germany/Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, the Brandenburg Medical School Theodor Fontane and the University of Potsdam, Senftenberg, Germany.
Martínez J; Montalban Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Roggenbuck D; Faculty Environment and Natural Sciences, Institute of Biotechnology, Senftenberg, Germany/Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, the Brandenburg Medical School Theodor Fontane and the University of Potsdam, Senftenberg, Germany.
Montalban X; Montalban Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2020 Dec 17, pp. 1352458520980141. Date of Electronic Publication: 2020 Dec 17.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials.
Autorzy :
Vidal-Jordana A; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. .
Rovira A; Sección de Neuroradiologia, Servei de Radiologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arrambide G; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Otero-Romero S; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Servicio de Medicina Preventiva y Epidemiologia. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Río J; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Comabella M; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Nos C; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Castilló J; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Galan I; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Cabello S; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Moncho D; Servicio de Neurofisiología Clínica. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rahnama K; Servicio de Neurofisiología Clínica. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Thonon V; Servicio de Neurofisiología Clínica. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rodríguez-Acevedo B; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Zabalza A; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Midaglia L; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auger C; Sección de Neuroradiologia, Servei de Radiologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sastre-Garriga J; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Division of Neurology. St. Michael's Hospital. University of Toronto, Canada.
Tintoré M; Servicio de Neurología-Neuroinmunología. Centro de Esclerosis Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Neurology [Neurology] 2020 Dec 16. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Modelling multiple sclerosis using induced pluripotent stem cells.
Autorzy :
Martínez-Larrosa J; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Matute-Blanch C; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Comabella M; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: .
Pokaż więcej
Źródło :
Journal of neuroimmunology [J Neuroimmunol] 2020 Dec 15; Vol. 349, pp. 577425. Date of Electronic Publication: 2020 Oct 17.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Induced Pluripotent Stem Cells/*physiology
Multiple Sclerosis/*physiopathology
Multiple Sclerosis/*therapy
Neural Stem Cells/*physiology
Cell Differentiation/physiology ; Humans ; Induced Pluripotent Stem Cells/transplantation ; Neural Stem Cells/transplantation ; Stem Cell Transplantation/methods ; Stem Cell Transplantation/trends
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review.
Autorzy :
Filippi M; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Istituto di Ricovero e di Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.; Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy.
Preziosa P; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Istituto di Ricovero e di Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.; Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Barkhof F; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Location VU University Medical Center (VUmc), Multiple Sclerosis Center Amsterdam, Amsterdam, the Netherlands.; Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom.
Chard DT; Nuclear Magnetic Resonance (NMR) Research Unit, Queen Square Multiple Sclerosis Centre, University College London Institute of Neurology, London, United Kingdom.; National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, United Kingdom.
De Stefano N; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Fox RJ; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, Ohio.
Gasperini C; Department of Neurology, San Camillo-Forlanini Hospital, Rome, Italy.
Kappos L; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland.
Montalban X; Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.; Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Moraal B; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Location VU University Medical Center (VUmc), Multiple Sclerosis Center Amsterdam, Amsterdam, the Netherlands.
Reich DS; Translational Neuroradiology Section, Division of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
Rovira À; Neuroradiology Section, Department of Radiology (IDI), Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Toosy AT; Nuclear Magnetic Resonance (NMR) Research Unit, Queen Square Multiple Sclerosis Centre, University College London Institute of Neurology, London, United Kingdom.
Traboulsee A; MS/Magnetic Resonance Imaging (MRI) Research Group, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.; Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Weinshenker BG; Department of Neurology, Mayo Clinic, Rochester, Minnesota.
Zeydan B; Department of Neurology, Mayo Clinic, Rochester, Minnesota.; Department of Radiology, Mayo Clinic, Rochester, Minnesota.
Banwell BL; Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.; Department of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Rocca MA; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Istituto di Ricovero e di Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.; Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Pokaż więcej
Źródło :
JAMA neurology [JAMA Neurol] 2020 Dec 14. Date of Electronic Publication: 2020 Dec 14.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
Autorzy :
DeLuca J; Kessler Foundation, 1199 Pleasant Valley Way, West Orange, NJ 07052 USA and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark 07103, NJ, USA. Electronic address: .
Schippling S; Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital and University of Zürich and Neuroscience Center Zürich, University of Zürich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland and Federal Institute of Technology (ETH) Zürich, Rämistrasse 101, 8092 Zürich, Switzerland. Electronic address: .
Montalban X; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Pg. Vall d'Hebron, 119-129, 08035 Barcelona, Spain. Electronic address: xavier.montalban@cem-cat.org.
Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland. Electronic address: .
Cree BAC; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, 675 Nelson Rising Lane, San Francisco, CA 94158 USA. Electronic address: .
Comi G; Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, via Olgettina 48, 20132 Milan, Italy. Electronic address: .
Arnold DL; NeuroRx Research and Montréal Neurological Institute, McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada. Electronic address: .
Hartung HP; Department of Neurology, Medical Faculty, Heinrich-Heine University, University Hospital Dusseldorf, Moorenstr. 5 40225 Dusseldorf, Germany. Electronic address: .
Sheffield JK; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. Electronic address: .
Liu H; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. Electronic address: .
Silva D; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. Electronic address: .
Cohen JA; Department of Neurology, Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 USA. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Dec 10; Vol. 48, pp. 102673. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Chitinases and chitinase-like proteins as biomarkers in neurologic disorders.
Autorzy :
Pinteac R; From the Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.
Montalban X; From the Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.
Comabella M; From the Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. .
Pokaż więcej
Źródło :
Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2020 Dec 08; Vol. 8 (1). Date of Electronic Publication: 2020 Dec 08 (Print Publication: 2021).
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Autorzy :
Wolinsky JS; Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: .
Arnold DL; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, QC, Canada; NeuroRx Research, Montreal, QC, Canada.
Brochet B; Department of Neurology, University of Bordeaux, Bordeaux, France.
Hartung HP; Department of Neurology, Universitätsklinikum Düsseldorf, Center of Neurology and Neuropsychiatry, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Montalban X; Neurology-Neuroimmunology Department and Neurorehabilitation Unit, Vall d'Hebron University Hospital, Barcelona, Spain.
Naismith RT; Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Manfrini M; F Hoffmann-La Roche, Basel, Switzerland.
Overell J; F Hoffmann-La Roche, Basel, Switzerland.
Koendgen H; F Hoffmann-La Roche, Basel, Switzerland.
Sauter A; F Hoffmann-La Roche, Basel, Switzerland.
Bennett I; F Hoffmann-La Roche, Basel, Switzerland.
Hubeaux S; F Hoffmann-La Roche, Basel, Switzerland.
Kappos L; Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.
Hauser SL; Department of Neurology, University of California, San Francisco, CA, USA.
Pokaż więcej
Źródło :
The Lancet. Neurology [Lancet Neurol] 2020 Dec; Vol. 19 (12), pp. 998-1009. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Disease Progression*
Antibodies, Monoclonal, Humanized/*pharmacology
Immunologic Factors/*pharmacology
Multiple Sclerosis, Chronic Progressive/*drug therapy
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Double-Blind Method ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Young Adult
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
U-turn speed is a valid and reliable smartphone-based measure of multiple sclerosis-related gait and balance impairment.
Autorzy :
Cheng WY; F. Hoffmann-La Roche Ltd, Basel, 4070, Switzerland. Electronic address: .
Bourke AK; F. Hoffmann-La Roche Ltd, Basel, 4070, Switzerland. Electronic address: .
Lipsmeier F; F. Hoffmann-La Roche Ltd, Basel, 4070, Switzerland. Electronic address: .
Bernasconi C; F. Hoffmann-La Roche Ltd, Basel, 4070, Switzerland. Electronic address: .
Belachew S; F. Hoffmann-La Roche Ltd, Basel, 4070, Switzerland. Electronic address: .
Gossens C; F. Hoffmann-La Roche Ltd, Basel, 4070, Switzerland. Electronic address: .
Graves JS; Department of Neurosciences, University of California, San Diego, San Diego, CA, 92093, USA; University of California, San Francisco, San Francisco, CA, 94143, USA. Electronic address: .
Montalban X; Division of Neurology, University of Toronto, Toronto, ON, M5S 1A1, Canada; Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (CEMCAT), Vall d'Hebron University Hospital, Barcelona, 08035, Spain. Electronic address: xavier.montalban@cem-cat.org.
Lindemann M; F. Hoffmann-La Roche Ltd, Basel, 4070, Switzerland; Department of Economics, Baden-Wuerttemberg Cooperative State University, Loerrach, 79539, Germany. Electronic address: .
Pokaż więcej
Źródło :
Gait & posture [Gait Posture] 2020 Nov 25; Vol. 84, pp. 120-126. Date of Electronic Publication: 2020 Nov 25.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score.
Autorzy :
Pérez-Miralles FC; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Río J; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Pareto D; Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vidal-Jordana À; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Auger C; Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arrambide G; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Castilló J; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Tintoré M; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Rovira À; Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Sastre-Garriga J; Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain. .
Pokaż więcej
Źródło :
Neuroradiology [Neuroradiology] 2020 Nov 25. Date of Electronic Publication: 2020 Nov 25.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Innovation in resident education - Description of the Neurology International Residents Videoconference and Exchange (NIRVE) program.
Autorzy :
Gros P; Division of Neurology, University of Toronto, Toronto, Canada; Division of Neurology, St Michael's Hospital, Toronto, Canada. Electronic address: .
Rotstein D; Division of Neurology, University of Toronto, Toronto, Canada; Division of Neurology, St Michael's Hospital, Toronto, Canada.
Kinach M; Telemedicine Program, St. Michael's Hospital, Toronto, Canada.
Chan DK; Division of Neurology, University of Toronto, Toronto, Canada; Division of Neurology, St Michael's Hospital, Toronto, Canada.
Montalban X; Division of Neurology, University of Toronto, Toronto, Canada; Division of Neurology, St Michael's Hospital, Toronto, Canada.
Freedman M; Division of Neurology, University of Toronto, Toronto, Canada; Division of Neurology, Mt. Sinai Hospital, Canada; Division of Neurology and Rotman Research Institute, Baycrest Health Sciences, Toronto, Canada.
Sasikumar S; Division of Neurology, University of Toronto, Toronto, Canada; Division of Neurology, St Michael's Hospital, Toronto, Canada.
Pokaż więcej
Źródło :
Journal of the neurological sciences [J Neurol Sci] 2020 Nov 08, pp. 117222. Date of Electronic Publication: 2020 Nov 08.
Typ publikacji :
Editorial
Opinia redakcyjna
Szczegóły
Podgląd okładki
Tytuł :
The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS.
Autorzy :
Tintore M; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arrambide G; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Otero-Romero S; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain/ Department Preventive Medicine and Epidemiology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Carbonell-Mirabent P; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Río J; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tur C; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain/Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK/Luton and Dunstable University Hospital, University College London, London, UK.
Comabella M; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Nos C; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arévalo MJ; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Anglada E; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Menendez R; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Midaglia L; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Galán I; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vidal-Jordana A; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Castilló J; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mulero P; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Zabalza A; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rodríguez-Acevedo B; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rodriguez M; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Espejo C; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sequeira J; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mitjana R; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology (IDI), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
de Barros A; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology (IDI), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pareto D; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology (IDI), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auger C; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology (IDI), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pérez-Hoyos S; Unitat d'Estadística i Bioinformatica, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Sastre-Garriga J; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rovira A; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology (IDI), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Servei de Neurologia/Neuroimmunologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain/Division of Neurology, University of Toronto, St Michael's Hospital, Toronto, ON, Canada.
Pokaż więcej
Źródło :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2020 Nov; Vol. 26 (13), pp. 1658-1669. Date of Electronic Publication: 2019 Oct 15.
Typ publikacji :
Journal Article
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 8174

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies